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1ECONOMIC EVALUATION OF NEWBORN HEARING
SCREENING PROCEDURES
Carmen Herrero and Juan D. Moreno-Ternero
ABSTRACT
In the past few years, there has been a growing interest in the medical lit-
erature about the study of the diﬀerent existing screening procedures to detect
hearing impairment in infants and young children. However, concerning their
economic evaluation, there are some important aspects, such as indirect costs,
which are not considered by that literature. Here, we present an economic eval-
uation of these screening procedures, using utility theory, to measure beneﬁts
of a health care program, i.e. a cost-utility analysis. The analysis is presented
from diﬀerent points of view, depending on the cost we would like to compute.
If we only consider direct costs, then targeted procedures, based on high risk
criteria are preferred. On the other hand, if indirect costs, such as special educa-
tion, and disability allowances were computed, then cost-utility analysis would
advocate for the implementation of universal screening procedures.
Keywords: Economic Evaluation; Cost Utility Analysis; Cost-Sensitivity Ra-
tios; Newborn Hearing Screening.
21I n t r o d u c t i o n
Recently, the Consellería de Sanitat de la Generalitat Valenciana, the health
care authority in the Comunidad Valenciana, a Spanish region, has edited a
protocol for the early detection of hearing impairment in newborns at this region
[8]. The protocol states the purpose, in the long run, of the implementation of a
universal newborn hearing screening (“UNHS” hereafter) program to detect the
impairments mentioned above. As a ﬁrst step, they decided to implement the
program to all infants who were born with a risk factor in the main hospitals.
When the screening protocol is only applied to those infants who were born
under a risk factor the program is said to be targeted newborn hearing screening
(“TNHS” hereafter). The election among the two possibilities (universal or
targeted) was a source of debate and it generated a wide literature about it,
in the last decade. However, this literature mainly focussed on the medical
aspects of the problem and it ignored considerably the economic viewpoint.
The objective of this paper is to make a cost-utility analysis by using the QALY
index to measure beneﬁts in health.
1.1 Background
At the beginning of 1993, the National Institutes of Health Consensus Develop-
ment Conference on Early Identiﬁcation of Hearing Impairment, addressed the
advantages of early (consequences of late) identiﬁcation of hearing impairment
[32]. Moreover, it concluded that universal screening should be implemented for
all infants within the ﬁrst 3 months of life.
The hearing impairment satisfy all the medical requirements to impose a
prevention program, by terms of a universal screening. On the one hand, it is a
serious handicap impairment, whose absence of early diagnostic will cause prob-
lems on language acquisition [30], [42]. Signiﬁcant hearing loss interferes with
the development of speech perception abilities needed for later language learn-
ing, e.g., meaningful language at the word, phrase, and sentence levels. These
impairments in communication skills can lead to poor academic performance
(especially reading), and ultimately, to limitations in career opportunities [18].
Moreover, it has a considerable prevalence, comparing with other illnesses for
which there exist universal newborn screening programs.1 Finally, there are re-
liable and sure screening methods, like Otoacoustic Emissions (OAE) and Audi-
tory Brainstem Responses (ABR), with high levels of sensitivity and speciﬁcity,
and the most important thing, there exists treatment (e.g., cochlear implants).
At the moment of the conference there was not any UNHS implemented.
There were only some programs based on the high risk criteria.2 The conference
pointed out two main disadvantages of these criteria. The principal one is that
approximately 50 percent of newborns with congenital hearing deﬁcits are not
in the high risk groups and are missed by the screen. Moreover, children who
1For instance, in Navarra, a Spanish region, there exists a universal newborn screening
program to detect phenylcetunoria, whose prevalence is of 1
3500 [18].
2For a complete list of risk factors of hearing impairment, see, for instance, [1] and [29].
3are not born in larger hospitals may not be routinely identiﬁed as being at risk.
Related to this, we have the second main disadvantage. The average age of
identiﬁcation in the United States remained closed to 3 years in 1993, which
coincides precisely with the end of the most important period for language and
speech development.
Since the conclusions of the conference were published, it seemed diﬃcult
to argument against the recommendation of the UNHS from a medical point
of view. This line of argument was followed by a large number of papers (see,
for instance [1], [3], [10], [13], [26], [36], [37], [41], and [42]). However, one year
later, Bess and Paradise [4], published a paper which argued strongly against
the UNHS. There were also subsequent papers which criticized UNHS (see, for
instance, [34]).
In the year 2000, the Joint Committee on Infant Hearing, published the
principles and guidelines for early detection and intervention programs [22]. In
this statement, based on pilot experiences which took place in some states of
the USA, (e.g. [3], [26], [37], [40]) they pointed out again the necessity of a
UNHS. As a matter of choice, the committee preferred a 2-stage procedure, in
which the ﬁrst stage is the OAE method followed by ABR, as a second stage
for those infants who failed the ﬁrst one.
The purpose of our work is to make a cost-utility analysis of the two cri-
teria. The two main sources of the data are two previous works. On the one
hand, we have Kemper and Downs’s paper [23], which collects information about
strategies, cost, and prevalence, reﬂected in previous works, and it presents a
cost-eﬀectiveness analysis of both criteria, the universal one and the targeted
one. This analysis, neither makes use of utility theory to measure the beneﬁts of
each alternative, nor takes into account the indirect costs, like special education
and disability allowances. On the other hand, Kezirian et al. [24] also present a
cost-eﬀectiveness analysis, but they do about four diﬀerent universal screening
techniques which are currently in use in most of USA hospitals, which actually
carry out a universal procedure for early hearing impairment detection. Further-
more, they ﬁxad i ﬀerent threshold for hearing impairment. In fact, Kezirian et
al., consider as a hearing impairment, bilateral or unilateral hearing loss above
30 dB, while Kemper and Downs do for ≥ 40 dB hearing loss bilaterally. As a
consequence, we will have diﬀerent prevalence data, depending on the threshold
we would like to consider.
Finally, we use data about a similar experience which took place for the ﬁrst
time in Spain at the end of the 90’s [18]. As in Kemper and Downs [23], the
threshold for the existence of hearing impairment under this third protocol was
ﬁxed in 40 dB.
The rest of the paper is organized as follows. First, we analyze some prop-
erties of the newborn hearing screening techniques mentioned above, and the
subsequent protocols, obtained as a result of their combinations. Secondly, we
focus on the diﬀerent kind of costs associated to a congenital hearing impair-
ment, and on how to measure health beneﬁts in terms of utility. Finally, we
present the results and conclusions.
42S c r e e n i n g s t r a t e g i e s
Screening is traditionally deﬁned as testing a population of asymptomatic in-
dividuals to identify unrecognized early disease or precursors of disease. The
screening procedure itself does not diagnose illness. Those who test positive are
sent on for further evaluation by a subsequent diagnostic test or procedure to
determine whether they do in fact have the disease. An implicit assumption un-
derlying the concept of screening is that early detection, before the development
of symptoms, will lead to a more favorable prognosis because the treatment be-
gun before the disease becomes clinically manifest and therefore, it will be more
eﬀective than later treatment. As we mentioned above, this is an assumption
clearly satisﬁed in the case of screening for hearing impairment.
The validity of a test is deﬁned as the ability of a test to distinguish between
who has a disease and who has not. Validity has two components: sensitivity
and speciﬁcity.T h e sensitivity of the test is deﬁned as the ability of the test
to identify correctly those who have the disease. The speciﬁcity of the test is
deﬁned as the ability of the test to identify correctly those who do not have the
disease (see Table 1 for further details). Obviously it would be desirable to have
a screening test that was both highly sensitive and highly speciﬁc. Usually that
is not possible, and there is generally a trade-oﬀ between the sensitivity and
speciﬁcity of a given screening test.
Screening is often carried out in stages, as for example in the issue we have
concerned. In such a case, a less expensive, less invasive, or less uncomfortable
test is carried out ﬁrst, and those who screen positive on this test are recalled
for further testing with a more expensive or more invasive test, which may have
greater sensitivity and speciﬁcity. It is hoped that bringing back for further
testing those who screen positive will reduce the problem of false positives.
On the question of early hearing impairment detection, there are two strate-
gies that have become available. Otoacoustic emissions (OAE) measures sounds
that are generated by the cochlea in response to acoustic stimulation [38]. They
are thought to represent a reﬂection of sound waves when sounds are presented
to normal ears, and they are not detected in ears aﬀected by the large majority of
types of hearing loss in newborns. Auditory Brainstem response (ABR) presents
sounds to the ear and detects nervous system activity in speciﬁc locations of
the hearing pathway. Complete ABR testing remains the gold standard for de-
termination of hearing loss, but there is a shorter screening version (S-ABR)
that is less expensive and quicker [24]. Automated devices for measurement of
O A Ea n dA B Ra r ea v a i l a b l e ,a n db o t ho ft h e mh a v er e p o r t e dh i g hs e n s i t i v i t y
and speciﬁcity levels.
Let us note that there is a lack of reliable data for sensitivity and speciﬁcity
of screening programs in the literature, specially in two-stages programs. To
solve this problem, notice that with the prevalence of congenital hearing loss
being relatively low, the speciﬁcity of the screening test is well approximated
by the share of infants who fail the test. About the sensitivity of a two-stage
program, it can be well approximated by the product of the sensitivity at each
stage.
5In 1999, the American Academy of Pediatry [1], pointed out that a UNHS
should be the long run objective. Now, it also prescribed that the used method-
ology should have a false positives rate below 3%, and a null false negatives rate.
As a matter of fact, they postponed to choose a speciﬁc method, while there
were not a method satisfying the above requirements, or at least, speciﬁcally
better than the other ones.
3P r o t o c o l s
The model of decision analysis about the newborn hearing screening is a 2-stage
protocol, similar to the one recommended by the National Institutes of Health
(NIH) [32] in 1993 (Figures 1 and 2). Universal 2-stage screening protocol,
consists of testing all newborns with OAE, as a ﬁrst stage, following by an ABR
test for those who failed the ﬁrst stage. The second stage used to be carried
out before the newborns would leave the hospital due to their accessibility. If
such is not the case, we face the problem of having a return rate (of babies
whose parents decide to come back for the second stage) about 79% [24]. This
procedure agrees with what we mentioned above, about the 2-stage screening
protocols. A less expensive test is carried out ﬁrst, and those who screen positive
on this test, are recalled for further testing with a more expensive, and eﬃcient,
test.
We present two slightly diﬀerent versions of this universal 2-stage screen-
ing, by changing some aspects of the OAE and ABR strategies. On the one
hand, we consider automated transient-evoked otoacoustic emissions (TEOAE)
as a ﬁrst stage, followed when indicated by automated auditory brainstem re-
sponse (ABR) testing [23]. We will refer this protocol as UNHS1 (Figure 1).
On the other hand, we consider otoacoustic emissions (OAE) as a ﬁrst stage,3
followed when indicated by a shorter screening version of automated auditory
brain response testing (S-ABR) [24]. We will refer this protocol as UNHS2 (Fig-
ure 2). Targeted screening reserves the two stage screening process for those
infants at risk for congenital hearing loss. Therefore, as before, we have two
alternative targeted screening procedures, which will be called TNHS1 (Figure
1) and TNHS2 (Figure 2). Every protocol concludes with a diagnostic test for
those who failed both stages. The diagnostic test is usually carried out after
the baby leaves the hospital, in order to ensure maxima levels of sensitivity and
speciﬁcity. Thus, we face again the problem of a low return rate.
T h ea n a l y s i si sb a s e do naﬁxed and deﬁned cohort of newborn children in
Spain. Some data from similar experiences in Canada and USA will be applied.
We assume that all newborns are screened by the 2-stage protocol and only 79%
of those who were classiﬁed as positives return for the diagnostic test [24]. We
also assume that each of these latter ones receive all necessary follow-up testing.
3There are two tests that are based on OAE: transient-evoked otoacoustic emissions
(TEOAE) and distortion product otoacoustic emissions (DPOAE). For this second proto-
col, the otoacoustic emissions tests were treated as a single entity because, following Kezirian
et al. [24], their cost and validity have been similar to date.
6Finally, there is a UNHS currently in practice in another Spanish region,
Navarra. In this case, the implemented protocol has three stages. The ﬁrst
stage consists on an OAE test to every newborn at the third day of life, before
leaving the nursery. For those who failed it, there will be a second OAE at the
ﬁfteenth day of life. Finally, the third stage involves those neonates who failed
the second stage to return at the third month, in order to receive a new OAE
test. Those who did not pass the third OAE test will go through a diagnostic
conﬁrmation by terms of an ABR test. We will refer to this protocol as UNHS3
and to its corresponding one, only referred to those infants who were born with
a high risk factor, as TNHS3 (Figure 3).
Table 2 summarizes the data of each screening protocol, including sensitivity,
speciﬁcity and costs. We can observe that UNHS2 presents the best level of
sensitivity, while TNHS1 is the one with the lowest cost.4
4C o s t s
Cost data are diﬃcult to obtain and standardize. For example, the cost of
using an automatic screening device depends on the time over which the device
will be depreciated and the estimation of the number of children who will be
screened [23]. We therefore evaluate costs based on reports in the literature.
Furthermore, there exists controversy in the literature with the cost of detecting
high-risk factors in newborns. The range of values provided by it, goes from
$0.50 to $15 [38], [41]. As we will see later, this cost will play a crucial role in
the cost-utility analysis from the perspective of a hospital (when indirect costs
are not evaluated).
Table 2 only shows direct costs of each screening test, namely OAE, ABR,
diagnostic and the cost of identifying high risk factors. These costs are enough
to present an analysis from the point of view of a hospital. By contrast, if we
want to present an analysis from other points of view, then we need to compute,
not only direct costs, but also indirect ones, such as follow-up and treatment,
special education and disability allowances. It seems plausible that if these costs
were evaluated, then the conclusions will diﬀer from the case in which they were
not evaluated.
A key recommendation of the recent Panel on Cost-Eﬀectiveness in Health
and Medicine was to carry the Cost-Eﬀectiveness analyses (“CEA” hereafter)
from a societal perspective, including all the costs and consequences of health
interventions [39]. Nonetheless, they also recommend that morbidity costs (pro-
ductivity gains and losses resulting from interventions that reduce morbidity)
should not be included among the costs in CEA. The Panel also says that true
social costs of lost productivity would be captured only by transfer payments
from disability insurance, and it recommends to include all health care costs
[39]. Meltzer and Johannesson [28], criticize these two recommendations of the
4For the purpose of a sensitivity analysis, conﬁdence intervals, for each screening method-
speciﬁc parameter values, were given in the table. In the case that the literature did not
provide them, the mean value was decreased and increased by 25%.
7Panel. On the one hand, they point out that excluding morbidity costs is likely
to lead to underestimating the CEA of interventions that enhance productivity
by decreasing morbidity [28]. On the other hand, if all health care costs were
included, it could lead to a double-counting, provided that people could incor-
porate personal ﬁnancial consequences into QALY weights [28]. Thus, according
to them, personal health care costs should not be included.5
Under our personal opinion that previous criticism to the Panel recommen-
dations only works if health costs are borne by the individual. If health costs
are bone by the Health Authority, they should be included. In our case, and in
the Spanish (or in general the European) perspective, where all costs are borne
by the Public Authority: health care (implants and treatments), education and
disability allowances, according to the Panel recommendations, we should con-
sider all sort of expenses (disability allowances can be understood as disability
insurance). And this case does not contradict the position in [28]. It would be
diﬀerent, according to the Panel recommendations, if some of the costs were
borne privately, as it happens in the US. In such a case, all follow up costs
should be excluded.
As a consequence, we will present the results from diﬀerent viewpoints, de-
pending on the costs we wish to consider. We will observe that results from
a “societal perspective” may be altered depending on the costs we introduce.
That is an additional evidence in the current debate introduced by Meltzer and
Johannesson, about the inconsistencies in the Panel on Cost-Eﬀectiveness in
Health and Medicine.
Related to this, we will assume that every newborn with hearing impairment
receives a treatment, but they do in diﬀerent points of time. There are two
possibilities. First, since early detection leads to a more eﬀective treatment, as
we mentioned in Section 2, we assume that an infant who receives the treatment
exactly after being detected by a screening procedure, will need neither special
education nor disability allowances. On the other hand, if the impairment was
detected without a screening program, then he would receive the treatment
after the maximum possible time to avoid some irremediable consequences, like
a misleading cognitive development, or speech perception. Consequently, he
would need special education and disability allowances.
As a result, for each of the available newborn hearing screening programs,
there will be four diﬀerent costs (per newborn) associated to it, concerning
the screening itself, the follow-up and treatment, the special education and
the disability allowances. More precisely, given a particular newborn hearing
screening program s, we will denote c1
s to its direct cost, c2
s to the treatment
costs associated to it, c3
s to its resulting special educational costs and c4
s to the
associated costs concerning disability allowances.
Now, in an economic evaluation of alternative health care programs, costs
must be computed with respect to a reference ‘status quo’. In other words,
5Meltzer and Johannesson position [28] would be also to compute some other costs, mor-
tality costs. Now, since the health programs that are being analyzed here (newborn hearing
screening) do not reduce mortality rates (they only reduce morbidity) those costs do not
appear in our case.
8the diﬀerent costs mentioned above must refer, indeed, to the incremental costs
associated to the change from the ‘status quo’ to the new situation, after im-
plementing the program. In the case of our work, we suppose that the ‘status
quo’ is the absence of any early detection program of hearing impairment, but
not the absence of any health policy concerning such an impairment, like treat-
ments, special education and disability allowances. As we mentioned above, we
assumed that every impaired newborn receives the same treatment, no matter
what screening procedure we decided to implement. The only diﬀerence is in the
precise point of time in which they receive it, which may alter considerably his
future consequences. Related to this, we assumed that those individuals whose
impairment was not eradicated after the treatment (every impaired newborn, in
the case of the ‘status quo’) receive special education and disability allowances.
As a consequence, the overall cost of treatments is reﬂected in the ‘status quo’ we
are considering, and therefore, the incremental treatment costs of each screening
program is null (i.e. c2
s =0 ).6 Furthermore, it is straightforward to see that
c3
s = −(p·ses·ce) and c4
s = −(p·ses·ρ),w h e r eses denotes the sensitivity of s, ce
the incremental cost of special education, ρ the disability allowances, and p the
prevalence of hearing loss.7 Depending on the viewpoint we consider to make














In [33] the educational costs for severely hearing-impaired and profoundly
hearing-impaired children are evaluated. From this study, savings in educa-
tional costs that would result from enabling the profoundly hearing-impaired
to function as severely hearing-impaired were determined. More precisely, the
discounted diﬀerence in education costs associated with a profoundly hearing-
impaired child as compared with a severely hearing-impaired over compulsory
school years (ages 4-16) was $42850. The improvements in the hearing impair-
ment have been found in children who received a cochlear implant at 4 years
and wore hearing aids after it. The same article shows that the discounted
value of a pediatric cochlear implant costs over 70 years of life is $109010.9 We
will assume that both amounts are estimations of the mean savings in special
education and treatment costs, respectively.
There is another important aspect we may wish to treat in the analysis of
6Since some individuals receive the same treatment earlier than others, there might be
diﬀerences in their costs, caused by the inﬂation. Notwithstanding, since we assume the same
horizon of life to every newborn, there might be diﬀerences about the cost of maintenance, as
well. For instance, if a newborn receives a cochlear implant two years before than other, then
the implant will be less costly, but he will incur in two more years of maintenance costs. We
will assume that both diﬀerences neutralize each other, which ensures c2
s =0 .
7The negative sign in c3
s and c4
s, refers to the fact that an early detection program produces
savings in special education costs and disability allowances, with respect to the status quo.
8As one can easily infer from our assumptions, and subsequent discussion, the analysis
from a hospital viewpoint coincides with the analysis from a health care authority viewpoint.
9The ﬁrst three years involve the assessment, implantation and rehabilitation, while the
remain ones refer to the maintenance.
9newborn hearing screening programs. Actually, there are many countries which
give disability allowances to people belonging to the deaf community. These
subsidies could even be such as those for the disabled people. Obviously, a
newborn hearing screening procedure would lead to save part of these public
subsidies.
In order to get concrete numbers from the last point, we used the data from
the European Union Home Panel, relative to Spain in the year 1994. In that
panel, we can observe that the mean of disability allowances is $4063 ($1=180
ptas.), which could be an estimation of the net earnings obtained by a deaf
individual in a year. If we compute this amount, discounted throughout the
working years, we have an estimation of $343709.
Table 3 summarizes all of these concepts, about the total costs of each pro-
cedure, with respect to the ‘status quo’. Note that all costs were rounded to the
nearest $.01.
5 Measuring beneﬁts in terms of utility
The importance of economic evaluation of health care programs raises the issue
of how to measure, value and incorporate changes in quality of life into the eco-
nomic evaluation. Cost Utility Analysis (“CUA” hereafter) is the most common
type of analysis used in health care decision making and it measures the beneﬁts
of a program in utility terms. More precisely, it measures changes in the quality
of life with the Quality Adjusted Life Years (“QALYs” hereafter) measure.
The evaluation of health care programs involves both technical and value
judgements. The value judgements concern mainly the trade-oﬀ between the
two important outcomes of such programs: quality of life gained and quantity
of life gained. QALYs oﬀer one way of incorporating these two beneﬁts of health
care programs into a single index measure: QALYs gained [5]. On the basis of
the QALY index, decisions concerning the allocation of resources in the health
care sector can be made. The program that should be implemented is the one
that oﬀers the largest number of QALYs per dollar or, what is equivalent, the
one that has the lowest costs per QALY gained [11]. For an extensive survey of
the advantages and disadvantages of this measure see, for instance, [31].
Once we decide to measure beneﬁts of a health care program by terms of
utility, with the QALY index, we need to decide how to assign quality weights to
each year provided by the program. Measuring preferences for health outcomes
is a very time consuming and complex task. A recent alternative that is being
widely used is to avoid the measurement task by using one of the pre-scored
multi-attribute health status classiﬁcation systems that exist [12]. Moreover,
Weinstein et al. [39], recommend, for a reference case, the use of a generic
health measure, which can be applied to a wide set of conditions and diseases.
Examples of such measures are the EuroQol (EQ-5D) and the Health Utilities
Index (HUI). Both measures assign to each patient a particular health status,
among a set of available ones. To do this, the authors assume that the health
can be characterized by a set of scores assigned to a ﬁnite number of aspects of
10the health status. These aspects are referred as dimensions or attributes. In the
case of the EQ-5D, there are ﬁve dimensions and three levels for each dimension:
no problems, some problems and extreme problems. In the case of the HUI, the
number of dimensions, and even the number of levels for each attribute can vary
(See the Appendix for the details). The EQ-5D was implemented in the 90’s
and it is often used in the evaluation of health programs, specially in Europe.
On the other hand, the HUI measure ﬁts better for pediatric purposes, due to
the fact that it is valid for patients over 2 years, while the EQ-5D is only valid
over 16 years.
In order to get the total beneﬁts (QALYs) of a particular program, we divide
the whole population of newborns in four groups, depending on their prevalence
and their test results, i.e., true positives, false positives, false negatives and true
negatives. Each of these groups will be characterized by a diﬀerent health status,
provided by each of the above measures we decide to use. The total QALYs
gained, associated to a particular program, will be the diﬀerence between the
aggregation (weighted by the cardinality of each group) of the QALYs associated
to each of these four groups, and the number of QALYs in the same population,
without implementing any program.
Table 4 shows the estimation of the beneﬁts provided by each of the four
protocols we are considering, with each of the two generic measures mentioned
above. This was done by reviewing the literature and by asking some experts
in the issue (See the Appendix for the details).
Once we have measured the beneﬁts and the costs of each alternative, deci-
sions about the implementation of a screening procedure can be made. If there
exists a procedure which is the less expensive and it provides the highest ben-
eﬁts (measured in QALYs gained) then that one should be implemented. In
general, decisions are not so trivial and there is a trade-oﬀ between the program
that minimizes the costs and the one which gives the highest number of QALYs.
In such a case, CUA refers to the Cost-Utility ratios (“CU ratios” hereafter),
i.e. the cost per QALY gained. The preferred screening procedure would be
the one which shows the lowest CU ratio. In other words, CUA advocates for
implementing that screening procedure with the lowest cost per unit of utility
gained, or what is equivalent, the program that oﬀers the highest number of
QALYs per dollar.
Notwithstanding, let us see that, under an additional assumption, CUA can
be reduced to a simpler analysis in which only the costs and the sensitiveness, of
each program, matter. The assumption is that the utility of a false positive indi-
vidual is the same than that of a true negative individual. The reason to do this
is the following. Since false positives are correctly identiﬁed in a short period of
time (undoubtedly, before the treatment starts), the possible utility diﬀerences
between such an individual and a true negative one, cannot be captured by any
dimension of each of the generic measures considered here. Notice that the only
diﬀerence between two individuals without congenital hearing impairment, but
with diﬀerent test results, lie in the hypothetical depression caused by a wrong
positive test. But, it is plausible to think that newborns do not usually get
depressed.
11Notice that, concerning the measurement of the beneﬁts of each alternative,
we only compute the health beneﬁts of the newborns, without paying attention
to the parents’ utility. One could argue that with this assumption we would
be bypassing an important negative externality, noting that the hypothetical
anxiety or depression provoked by a false positive test, could be translated to
the patient’s parents. Nevertheless, recent papers have shown that the eﬀect
of these cases on the parental anxiety is not so important (see, for instance,
[7] and [35]). Furthermore, it is not less true that if the hypothetical parental
anxiety would be considered as a negative externality, then we should also take
into account a positive externality caused by the care that the patient obtains
from her parents, which could help considerably to her treatment. Without any
doubt, this would increase exponentially the diﬃcult task of computing health
beneﬁts, and as a result, we will restrict our attention to the patients’ utility.
Given a newborn hearing screening procedure s, let us deﬁne its cost-sensitivity
ratio (“CS ratio” hereafter), as the ratio between its total cost cs,a n di t ss e n -
sitivity ses.I no t h e rw o r d s ,i fRs denotes the CS ratio, then Rs = cs
ses.N o t i c e
that cs depends on the viewpoint from which we are making the analysis. The
proof of the following result is shown in the Appendix.10
Claim 1 Under the assumptions mentioned above, the screening procedure that
should be implemented, according with a CUA, is the one that shows the lowest
CS ratio.
As a result, and in the case of non-trivial decisions, we simply need to cal-
culate the CS ratios of each alternative to select the best option. This would
imply that the recommended program by a CUA would be independent on the
generic utility measure we would decide to choose. Nonetheless, the claim only
provides ordinal preferences among the set of possible alternative programs.
Consequently, in order to get cardinal preferences among them, we will also
show the CU ratios, provided by each of the generic measures mentioned above.
Furthermore, these CU ratios will also show the necessary cost to gain a QALY
in each program, which is an interesting information by itself.
In the QALY model, there exists the possibility of introducing time prefer-
ences, by terms of a (constant or variable) discount rate.11 If such is the case,
obviously the CU ratios would be greater than in the general case. The cost per
QALY gained would increase as long as the discount rate also does. Obviously,
a discount rate would be an uncertain parameter in the model, and a sensitivity
10Strictly speaking, the proof of the claim requires that the utility associated to a generic
false positive individual would be greater than the one associated to a false negative individual.
We did not mentioned explicitly this assumption before, but obviously we did implicitly.
Otherwise, it would be unnecessary to implement any early detection program.
11When a discount rate r is considered, the number of QALYs of a health stream with a









12analysis (the main method by which analysts have allowed for uncertainty in
economic evaluations [12]) for it, would be required. However, the above claim
tells us that the ordinal preferences among the set of available programs do not
depend on the discount rate either, which would solve the uncertainty about
the election of it. (See the proof of the Claim in the Appendix)
6R e s u l t s
As we mentioned above, there are diﬀerent results in the CUA, depending on
the viewpoint we wish to consider or, what is equivalent, depending on the costs
we would like to compute.
6.1 CUA from the hospital point of view
In this ﬁrst case, we simply compute the direct costs of the health care system,
namely the cost of each screening procedure and the subsequent deﬁnitive diag-
nostic test. In such a situation, targeted procedures are less expensive programs
but the universal procedures are the ones which produce the highest beneﬁts.
Therefore, we need to look at the CS-ratios to decide.
Table 5 shows the medical cost-utility (MCU) ratios, and the CS ratios from
a hospital viewpoint.12 It follows from the data in the table, that the targeted
procedures are the ones which give better ratios. In particular, TNHS2 is the
one which presents a better CS ratio. Therefore, according to a CUA from a
hospital viewpoint, TNHS2 should be the one implemented, among the programs
considered here. More precisely, from a hospital viewpoint, we would have the
following order of preferences among the set of available programs:
TNHS2 Â TNHS3 Â TNHS1 Â UNHS1 Â UNHS3 Â UNHS2,
where Â means “strictly preferred to”.13
As we mentioned in Section 5, this conclusion is independent on the generic
utility measure chosen and on the discount rate. The sensitivity analysis tells
us that the uncertainty with respect to the cost of detecting a high risk factor
on a newborn has substantial inﬂuence, because of its wide conﬁdence interval.
In particular, if it would increase from its mean estimation $1,t o$6.17,t h e n
the universal procedure UNHS1 would lead to a lower CS ratio.14 The other
parameter that has a considerable inﬂuence is the sensitivity. Since the conﬁ-
dence intervals of it, for some procedures, are also wide enough, it might alter
the preferences within the targeted or universal procedures. However, the main
conclusion, namely targeted procedures are preferred to universal ones, is still
true for any sensitivity values, within their conﬁdence intervals.
12The life horizon of a newborn considered here was 74 years.
13Notice that in any case the procedures corresponding to the Spanish protocol (TNHS3
and UNHS3) lie in between the other two possibilities.
14Note that the conﬁdence interval for the cost of detecting a high risk factor on a newborn
is [$0.5,$15] (see [23]). Thus, such an increment, from $1 to $6.17,w o u l dn o tb es os t r a n g e .
13For the sake of completeness, we show in Table 5 the MCU ratios from a hos-
pital viewpoint provided by the EQ-5D and HUI measures, without discounting
ﬁrst, and with a discount rate of 0.05. The diﬀerence between them is that all of
the ratios, provided by the EuroQol measure, are higher than the corresponding
ones obtained with the HUI. Thus, it is more expensive to gain a QALY, if we
measure beneﬁts with the EQ-5D measure. This is due to the fact that the HUI
measure provides higher gains of utility (See the Appendix for the details).
6.2 CUA from the Health Care Department point of view
Now, not only the direct costs of a newborn hearing screening procedure, but
also the subsequent follow up and treatments, will be ﬁnanced from the Health
Care Institution budget.15 Therefore, from this new viewpoint we should also
consider these latter costs. However, as we mentioned above, we assume that
the treatment costs are the same to each screening method s,a n dt h e r e f o r e
the total costs of each one increase in the same proportion. Moreover, these
are also costs included in the ‘status quo’. In other words, even in the case
that no early detection program exists, every infant with congenital impairment
receives a treatment. As a consequence, the costs associated to each of the
available screening programs, with respect to the ‘status quo’ would coincide
with the direct costs, and therefore, the CUA from the Health Care Authority
point of view, would be exactly the CUA from the Hospital viewpoint.
6.3 CUA from a “Societal Perspective”
Finally, we present another viewpoint in which we also include the remaining
costs associated to a newborn hearing screening procedure, i.e. special educa-
tional costs and disability allowances.
Under this perspective, the early detection programs would not only provide
health beneﬁts with respect to the ‘status quo’, but also savings in special
education costs and disability allowances. More precisely, as we mentioned in
Section 4, each screening program s w o u l ds a v ea na m o u n t( p e rn e w b o r n )o f
p·ses ·(ce+ρ) (p·ses ·ce, when disability allowances are not computed), where
ses denotes the sensitivity of s, ce the incremental cost of special education, ρ
the disability allowances, and p t h ep r e v a l e n c eo fh e a r i n gl o s s .
We can observe from Table 3 that UNHS2 is the program with the higher
savings, even in the case that we do not include disability allowances. More-
over, notice that the order of programs according to the savings they produce,
is exactly the same one that according to the beneﬁts (QALYs gained) they
produce, as Table 4 shows.16 More precisely
UNHS2 Â UNHS3 Â UNHS1 Â TNHS2 Â TNHS3 Â TNHS1,
15Recall that we assume a “European Perspective” in which all health costs are borne by
the Health Authority.
16In both cases, the ranking coincides with the ranking of sensitivity levels. As the proof of
the Claim shows, this is independent on the employed utility measure and discount rate.
14where Â means “strictly preferred to”. Notice that this is a totally diﬀerent
order to the one provided in Section 6.1. The sensitivity analysis says that such
a ranking is still valid when we vary the mean estimations of ce or ρ,w i t h i n
their conﬁdence intervals.17
As we pointed out in Section 4, and since the analysis presented here is
based on a ﬁxed and deﬁned cohort of newborn children in Spain, where all of
these costs are borne by the Public Authority, computing educational costs and
disability allowances does not contradict the position in [28], about the incon-
sistencies in the Panel on Cost-Eﬀectiveness in Health and Medicine. Notwith-
standing, if some costs were borne privately, the situation changes. In such a
case, all follow up costs should be excluded. As a result, the unique cost to be
computed would be the direct cost of each screening program. This framework
would coincide with the CUA from a hospital viewpoint, presented in Section
6.1, in which targeted screening programs would be preferred.
7 Discussion
We have presented here some ideas about the current debate concerning the
adequacy of an implementation of a newborn hearing screening program. Several
comments can be made about it, depending on the point of view from which we
wish to make the analysis. In other words, depending on the costs we wish to
compute, from each alternative.
As one could expect from the intuition, only evaluating the direct costs,
at a r g e t e ds c r e e n i n g ,b a s e do nh i g hr i s kf a c t o r sd e t e c t i o n ,w o u l db ep r e f e r r e d
to a universal one. This conclusion is still true when treatment (cochlear im-
plants) costs are included (Health Care Authority viewpoint). As far as we
are concerned about indirect costs, namely special education and future disabil-
ity allowances, then the conclusion reverses, i.e. a universal procedure would be
preferred. These conclusions support the reﬂections made by Meltzer and Johan-
nesson [27] and [28], about the inconsistencies in the Panel on Cost-Eﬀectiveness
in Health and Medicine. Those reﬂections suggest that accounting for future
costs in medical cost-eﬀectiveness analysis may substantially alter both the ab-
solute and relative cost-eﬀectiveness analysis of medical interventions. This is
indeed the case of our work. While an evaluation of direct costs advocates for
a targeted screening procedure, an estimation of indirect costs, in the case that
they were borne by the Public Authority, as it happens in most of the European
countries, advocates for a universal screening procedure.
Furthermore, the support of a UNHS holds just considering the indirect costs
of a newborn hearing screening program, associated to special education. As
far as we introduce other kind of indirect costs, like disability allowances, the
support is even stronger. Obviously, this would not be the case in countries,
17Furthermore, the conclusion would still be valid when disability allowances were not com-
puted, i.e. ρ =0 ,a n dce > 32137.5. In particular, such a condition is fulﬁlled for the mean
value of ce considered here. Since the conﬁdence interval for ce is [18374,67326] [33], disability
allowances need to be computed, in order to ensure the same ranking, for lower values of ce.
15where some of these indirect costs are borne by individuals.
Notice that the support for the UNHS, as a result of a cost-utility analysis
evaluating indirect costs, reinforces the support of it, that was also presented in
some previous works, from diﬀerent perspectives. For instance, cost-eﬀectiveness
analyses (c.f. [23], [24] and [25]) or analyses based on the study of the resulting
income distribution of the population (c.f. [17] and [21]).
The results have been obtained by evaluating health beneﬁts in terms of
utility, i.e. with the QALY index. More precisely, we used two generic health
measures, such as the EuroQol (EQ-5D) and the Health Utilities Index (HUI),
to assign quality weights to each year provided by each alternative health care
program. Under the plausible assumption of our model, i.e. the absence of
utility diﬀerences between false positives and true negatives, the ranking among
the set of available procedures does not depend neither on the generic measure,
nor on the discount rate we wish to consider, which diminishes considerably the
‘uncertainty eﬀect’ of our problem. Since the time for conﬁrming a false negative
is not high enough, the hypothetical anxiety caused by it, is not manifested in
the newborn yet. Furthermore, due to the fact that this conﬁrmation must be
done before starting any treatment, none of the other dimensions which comprise
each of the generic utility measures considered here will vary, between a true
negative and a false positive newborn. Therefore, the EQ-5D and the HUI will
assign the same quality weights to each of them, as our assumption asserts. The
main impact of false positives concerns to the hypothetical anxiety or depression
on their parents, but we pointed out that recent works (c.f. [7] and [35]) have
diminished the importance of this eﬀect.
Notwithstanding, depending on the employed measure we would like to com-
pute, the amounts provided by each cost-utility ratio, i.e. the cost per QALY
gained, and the relationship between the health beneﬁts and the savings of each
program, in the societal perspective, may vary. In other words, we have consen-
sus about ordinal preferences among the set of available programs, but a lack
of it, if we turn to cardinal preferences among them. Furthermore, we should
point out that we considered here the Spanish tariﬀse s t i m a t e df o rt h eE Q - 5 D
that are available [2], but that is not the case of the HUI system. The only
available scoring formula for the last version of the HUI system, is based on the
estimations made from a sample in Canada [15], and therefore, we used those
weights, which are the only available ones at the moment. As it can be observed
from Table 5, both measures provide signiﬁcantly diﬀerent amounts, concern-
ing the ratios. Furthermore, there are also EQ-5D tariﬀs, estimated from an
England survey [9], and these weights also lead us to diﬀerent ratios (See the
Appendix for the details). As a consequence, if we would like to get enough
consensus about the cardinal preferences among the set of available programs,
the above generic utility measures do not seem to be very appropriate. One
possible reason for this, is that they do no ﬁt exactly to our problem, specially
due to the fact that some dimensions of each measure (like anxiety or self-care)
do not have full sense when they refer to newborns. Thus, a possible line of
argument for future research could be to construct a speciﬁc utility measure for
this problem. Nevertheless, if we accept the assumptions mentioned above, the
16conclusions shown in our model, about the ordinal preferences among them, are
unobjectionable, even with the use of a more speciﬁc utility measure.
We have presented three diﬀerent protocols in the targeted and universal
procedures respectively, as a consequence of the three diﬀerent sources of data
employed here (c.f. [18], [23], and [24]). On the one hand, we presented two
diﬀerent protocols following the NIH recommendation [32], which are currently
in use in some hospitals of USA. The diﬀerence between both protocols can be
due to the fact that Kemper and Downs [23] base on the hypothetical protocol
recommended by the NIH [32], while Kezirian et al. [24] do it on a slight
diﬀerent version of this protocol, which is currently implemented in most of the
USA hospitals. Furthermore, since Kemper and Downs [23] ﬁxt h et h r e s h o l d
for serious hearing loss in ≥ 40 dB hearing loss bilaterally, while Kezirian et
al. [24] do it in ≥ 30 dB hearing loss unilaterally, we have diﬀerent prevalence
of hearing loss from both papers. On the other hand, we presented a diﬀerent
protocol which is currently in practice in some hospitals of a Spanish region.
This third protocol seems to be in the middle of the above ones, by terms of
preferences, but in any case the main conclusion, namely any UNHS is preferred
to any TNHS, still holds here, when indirect costs are computed.
Finally, about the treatment costs, we only included here the costs con-
cerning a cochlear implant, because it is the only treatment whose data and
eﬀectiveness is well established in the literature. Further research about other
alternatives, such as hearing aids, which is currently in use when moderate
hearing impairment exists, seems to be necessary, in order to generalize this
analysis. Moreover, further medical research and consensus about the protocols
used here, seems to be necessary too, in order to conﬁrm crucial data for their
economic evaluation, such as sensitivity.
Let us also note that we have supposed that all treatments are successful in
true positives newborns. In other words, once they receive the treatment, they
do not need neither special education, nor disability allowances. However, this is
not the case of the false negatives. These latter individuals receive a treatment
but, since it was not an early treatment, they will also need special education,
and future disability allowances. Both of these assumptions could have been
relaxed in the following way. We could have supposed that everybody receives
the treatment, but there is a higher probability of success when this treatment
is received after an early detection, by terms of a screening procedure (See [21],
for a similar study). Theoretically, this could have been done, but since there
is no clear evidence about these probabilities of success in the literature, the
uncertainty parameters of the model would have been increased and therefore,
it would turn it less tractable from a practical viewpoint.
To conclude, as one can infer from our model, and the subsequent sensitivity
analyses, the sensitivity (obviously, apart from the costs) becomes the crucial
data of each alternative. This is particularly meaningful when the impact of
false positives is diminished as it can be inferred from the literature, in the
case of our problem. Under our opinion, this should induce specialists to reﬁne
protocols in order to look for better levels of sensitivity, even at the cost of
presenting worse levels of speciﬁcity. Obviously, that should be done taking into
17account the trade-oﬀ between cost and sensitivity which is reﬂe c t e di nw h a tw e
called cost-sensitivity ratios. However, this may be a hard task for specialists,
and therefore it should be done by health policy makers, as part of an ensuing
economic evaluation.
188A p p e n d i x
In this section, we present an explanation of the utility weights, given by each
measure of beneﬁts, EQ-5D and HUI, to each of the resulting groups after the
implementation of a particular screening procedure. Furthermore, we give the
P r o o fo ft h eC l a i m .
8.1 EuroQol measure (EQ-5D)
The EQ-5D descriptive system, developed by the EuroQol Group, classiﬁes pa-
tients into 243 health states plus the states death and unconscious. Once the
patient has been classiﬁed into such a health state, the researcher can assign a
relevant value. These values are based on previous research where usually not
all the values of the possible health states have been measured.
One of the methodological starting points of the EuroQol Group was the
assumption that health can be characterized by a set of scores applied to ﬁve
aspects of health status. The EQ-5D refers to these aspects as dimensions. In
particular, the EQ-5D refers to ﬁve dimensions: mobility, self-care, usual ac-
tivities, pain or discomfort, and anxiety or depression.18 The dimensions each
comprise three levels: no problems, some or moderate problems, and extreme
problems or unable to. Within the EQ-5D classiﬁcation system, every individ-
ual health state can be described by a row vector − → x =( x1,...,x5),i nw h i c h
the element xi represents the score on dimension i.T h u s , x1 is the score on
mobility, x2 is the score on self-care, etc. The score on a dimension is ‘1’i fi t
is the highest level and ‘3’ if it is the lowest. For example, a health state such
as: some problems in walking about, no problems with self-care, no problems
with performing usual activities, moderate pain and moderate anxiety could be
represented by the row vector (2,1,1,2,2), usually abbreviated to 21122.T h i s
notation is used throughout this work. The states death and unconscious cannot
be described within the classiﬁcation system.
In our problem, the EQ-5D measure provides the following quality weights,
which were obtained by reviewing the literature and by asking some experts
in the issue. First of all, as we mentioned above, we assigned the same utility
weights to those individuals without congenital impairment, independently of
their test results. Let us now consider the utility gains of those impaired new-
borns who were correctly identiﬁed after a screening procedure (true positives)
compared with those who were not (false negatives).
We consider that there are no diﬀerences between them from the birth to the
beginning of the treatment, not far away of the sixth month of life, as the NIH
recommend [32]. We estimated three years and a half, for the subsequent treat-
ment of a true positive newborn, including the possibility of a cochlear implant
at the fourth year of life, hearing aids, and the deaf community language’s learn-
ing, which will help the children in the communication with her parents ﬁrst
and with the rest of the society on a second step. Since the hearing impairment
18See [6] or [12], among others, for further details about the EQ-5D measure.
19detection point of time is estimated in the mean age of 3 years [32], we assume
that there is a utility loss, from the sixth month to the third year, caused by
the hypothetical pain of the treatment. Namely, a health status of 11121 for the
true positive individual and 11111 for the false negative one. Finally, after the
fourth year, and once the treatment has been ﬁnished, we assume that the true
positive individual reaches the perfect health status, while the false negative one
reaches only 11212. This will remain constant throughout the remain 70 years
of life.19 To summarize, and considering that the total number of true positives
provided by a screening program s is p · ses,w h e r ep denotes the prevalence of
hearing loss and ses denotes its sensitivity, the utility gains would be




(U(11121) − U(11111)) + 70(U(11111) − U(11212))
¶
=1 7 .4305 · p · ses.
The utility weights were obtained from the Spanish tariﬀse s t i m a t e df o rt h e
EQ-5D, that are available [2]. There are also EQ-5D tariﬀs, estimated from
an England survey [9], which would give us a signiﬁcantly diﬀerent amount of
QALYs gained (12.65·p·ses). As a consequence, this would produce signiﬁcantly
diﬀerent ratios. About the discounted number of QALYs, with a discount rate
of 0.05, the utility gains would be 3.79 · p · ses (2.66 · p · ses i nt h ec a s eo ft h e
English weights).
8.2 Health Utilities Index measure (HUI)
There are three HUI systems: HUI1, HUI2, and HUI3. Each system consists of
a health status classiﬁcation system and one or more scoring formulae. As in the
EQ-5D, in all cases the scores are preference-based, interval-scaled, and on the
0 (dead) to 1 (perfect health) value scale. Scores are derived from preferences
of members of the general public. The systems were developed over time, each
building in part on the previous one. The HUI1 system only considered four
attributes, and it was originally developed for the evaluation of outcomes, in-
cluding indirect ones, of neonatal intensive care, but was later used more broadly
(See [11], for further details about it, and [31] for an application of it to our
problem). The HUI system was further extended, specially for paediatric appli-
cations, resulting in the HUI2 system. The HUI2 system comprises six attributes
and preferences for its scoring function were measured on a random sample in
Canada (See [12], for further details about it, and [31] for an application of
it to our problem). Finally, the HUI3 classiﬁcation system was based closely
on that of the HUI2. The sensory attribute of HUI2 was expanded in HUI3
into the three attributes: vision, hearing and speech. The remain changes were
made to increase the structural independence of the attributes, and therefore
the estimation of the scoring system was simpliﬁed. As with the HUI2 system,
preferences for the HUI3 were measured on a random sample in Canada (See
[12], [14] or [15] for further details about it). To summarize, within the HUI3
19Recall, that we assume a life horizon of 74 years.
20classiﬁcation system, every individual health state can be described by a row
vector − → x =( x1,...,x8),i nw h i c ht h ee l e m e n txi represents the score on dimen-
sion i. More precisely, x1 is the score on vision, x2 is the score on hearing, x3 is
the score on speech, x4 is the score on ambulation, x5 is the score on dexterity,
x6 is the score on emotion, x7 is the score on cognition and x8 is the score on
pain. The dimensions each can comprise a diﬀerent number of levels. It can be
observed that, since there is a speciﬁc attribute which concerns hearing status,
this measure ﬁts better to our problem.
In our problem, the HUI3 measure provides the following quality weights.
We proceed in the same manner than in the case of the EQ-5D, but with the
new scoring function. As a result, the utility gains would be




(U(11111112) − U(11111111)) + 70(U(13211211) − U(15311321))
¶
=2 6 .71 · p · ses.
About the discounted number of QALYs, with a discount rate of 0.05, the utility
gains would be 6.28 · p · ses.
8.3 Proof of the Claim
Given a screening procedure s, let us denote its costs by cs,a n db yQs the utility
gains (in QALYs) after implementing it. Thus, its CU-ratio, i.e. the cost per
QALY gained that oﬀers, is cs
Qs. For the sake of completeness, let us denote by
ses the sensitivity of s,a n db yp the prevalence of hearing loss. Now, under our
assumption, there are not utility diﬀerences between those newborns without
congenital impairment, even when they got diﬀerent results in the screening test.
As a consequence, the utility gains provided by a screening program refer to
those newborns, whose congenital impairment was detected after the screening
test, and therefore, they were referred for the subsequent treatment (i.e. the
true positives). If u1 denotes the utility of a newborn’s health proﬁle when its
impairment was detected thanks to the screening, and u2 when it was not, then
the utility gains are the following:20
Qs = p · ses · (u1 − u2),
where p·ses is the proportion of true positives after implementing the screening
procedure s.N o t i c et h a tui depend on the generic utility measure, and on the




= k · Rs,
where k = k(u,r,p)= 1
p·(u1−u2) > 0,a n dRs = cs
ses is what we called the
CS-ratio. Note that k is a positive value which depends on the prevalence of
20Assume u1 >u 2.
21hearing loss, and the chosen discount rate and utility measure. However, k is
not screening method-speciﬁc. In other words, k is constant for every screening
procedure s. As a result, the program which oﬀers the lowest CU-ratio, i.e. the
one that CUA would recommend for implementing, is the program which oﬀers
the lowest CS-ratio. ¥







Positive (T+) a b a + b
Negative (T −) c d c + d
Total a + c b + d a + b + c + d = q
Sensitivity (se) se = P(T+|S+)= a
a+c
Speciﬁcity (sp) sp = P(T−|S−)= d
b+d
Prevalence (p) p = a+c
q
True positives (a) a = p · se · q
False positives (b) b =( 1− p) · (1 − sp) · q
False negatives (c) c = p · (1 − se) · q
True negatives (d) d =( 1− p) · sp · q
Table 1: Congenital impairment status












































































TNHS1 0.11% 1.59 −20.234 −195.284
TNHS2 0.11% 1.65 −23.426 −224.564
TNHS3 0.11% 1.57 −21.79 −209.167
UNHS1 0.11% 10.05 −26.904 −323.318
UNHS2 0.11% 13.91 −28.629 −369.846
UNHS3 0.11% 11.68 −27.913 −345.501
TNHS1 0.35% 1.59 −67.845 −624.829
TNHS2 0.35% 1.65 −78.137 −718.123
TNHS3 0.35% 1.57 −72.758 −668.955
UNHS1 0.35% 10.05 −107.53 −1050.67
UNHS2 0.35% 13.91 −121.442 −1207.13
UNHS3 0.35% 11.68 −114.299 −1124.8
Table 3: Incremental costs (per newborn) with respect to the ‘status quo’.
PROC. PREV. QALYs gained (r =0 .05)
EQ-5D HUI3 EQ-5D HUI3
TNHS1 0.11% 0.009 0.014 0.0019 0.0032
TNHS2 0.11% 0.010 0.016 0.0022 0.0037
TNHS3 0.11% 0.009 0.015 0.0021 0.0034
UNHS1 0.11% 0.015 0.023 0.0033 0.0054
UNHS2 0.11% 0.017 0.027 0.0038 0.0062
UNHS3 0.11% 0.016 0.025 0.0035 0.0058
TNHS1 0.35% 0.028 0.043 0.0061 0.0102
TNHS2 0.35% 0.032 0.050 0.0071 0.0117
TNHS3 0.35% 0.030 0.046 0.0066 0.0109
UNHS1 0.35% 0.048 0.073 0.0104 0.0172
UNHS2 0.35% 0.055 0.084 0.0120 0.0198
UNHS3 0.35% 0.051 0.079 0.0111 0.0185
Table 4: QALYs gained (per newborn).
24PROC. PREV. CS-RATIOS MCU-RATIOS (r =0 .05)
EQ-5D HUI3 EQ-5D HUI3
TNHS1 0.11% 3.434 179.107 116.882 823.547 497.203
TNHS2 0.11% 3.101 161.759 105.562 743.78 449.045
TNHS3 0.11% 3.168 165.221 107.821 759.697 458.655
UNHS1 0.11% 12.819 668.571 436.298 3074.13 1855.96
UNHS2 0.11% 15.413 803.854 524.582 3696.17 2231.5
UNHS3 0.11% 13.905 725.205 473.257 3334.54 2013.17
TNHS1 0.35% 3.434 56.2909 36.7345 258.829 156.264
TNHS2 0.35% 3.101 50.8387 33.1765 233.759 141.128
TNHS3 0.35% 3.168 51.9267 33.8865 238.762 144.149
UNHS1 0.35% 12.819 210.122 137.122 966.155 583.3
UNHS2 0.35% 15.413 252.64 164.869 1161.65 701.33
UNHS3 0.35% 13.905 227.922 148.738 1048 632.712















































































































Figure 3: UNHS3 Vs. TNHS3
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